ClinicalTrials.gg
RecruitingNCT07682948Updated Jul 6, 2026

A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers

A Phase 1 interventional study of Investigational Product 1 and Investigational Product 2 in Hypertension and Dyslipidemia, sponsored by Korea United Pharm. Inc.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Korea United Pharm. Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 54 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Hypertension with a site in Korea, Republic of — 30 open to participants now, 41 under way, 11 of them phase 3. Hypertension · Korea, Republic of.

Planned enrollment
261st of 304
36 · median 110
Started
2026
with 10 others
Phase 1
102 of 353
6 open now
Primary completion
2026-09
later than 23 of 40 live
Registered
347th of 353
by date

Among the 353 studies in Hypertension with a site in Korea, Republic of, this one is the 261st largest by planned enrollment of the 304 interventional ones that give a count, is one of 11 that started in 2026, is one of 102 in phase 1, reaches primary completion later than 23 of the 40 other live ones, and was the 347th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

30 of the 353 studies in Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 19 Years to 54 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Hypertension with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers

03

Conditions studied

  • Hypertension
  • Dyslipidemia
04

Who can participate

Ages eligible
19 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 19 years or older and less than 55 years at the screening visit.
  • Subjects with a body weight of at least 50 kg (at least 45 kg for females) and a (BMI) of 18.0 kg/m² or higher and 30.0 kg/m² or lower at the screening visit.

BMI (kg/m²) = Body weight (kg) / Height (m)²

  • Subjects who have no congenital or chronic diseases and no pathological symptoms or findings based on medical examination at the screening visit.
  • Subjects determined to be eligible for participation in the clinical trial by the Investigator (or delegated Sub-investigator) based on the evaluation results of hematology, blood chemistry, serology, urinalysis, other clinical laboratory tests, physical examination, and (ECG), which are established and performed according to the characteristics of the product.
  • Subjects who agree that they and/or their spouse or partner will use highly effective (excluding hormonal contraceptives) from the first administration of the investigational product until 14 days after the last administration to prevent pregnancy and who agree not to donate sperm or ova.

    • Highly effective methods of contraception: intrauterine device (IUD), bilateral tubal occlusion, vasectomized partner, sexual abstinence.
  • Subjects who have received and understood sufficient explanation regarding the purpose, procedures, characteristics of the investigational product, and anticipated adverse events of this clinical trial, and who have voluntarily signed the form.

Exclusion criteria

Exclusion Criteria:

  • Subjects with current or past history of diseases involving the renal system (e.g., severe renal impairment), nervous system (e.g., cerebrovascular disease), immune system, respiratory system (e.g., bronchial asthma), urinary system, gastrointestinal system, endocrine system (e.g., congenital lipid metabolism disorders, severe diabetes mellitus), hematologic/oncologic system, cardiovascular system (e.g., severe hypertension, heart failure, coronary artery disease), reproductive system (e.g., endometrial hyperplasia, endometriosis), psychiatric disorders, or myopathy.
  • Subjects with a history of gastrointestinal surgery (except simple appendectomy or hernia repair) that may affect drug absorption, or with gastrointestinal disease.
  • Subjects with severe hepatic impairment, biliary obstruction, or cholestasis (this drug is excreted almost entirely via bile. Cholestasis, biliary obstructive disease, or hepatic impairment may be expected to reduce hepatic clearance.).
  • Subjects with active liver disease or persistent elevation of aminotransferase levels of unknown cause.
  • Subjects with hereditary angioedema or a history of angioedema during treatment with an ACE inhibitor or an angiotensin II receptor blocker.
  • Subjects who have taken enzyme-inducing or enzyme-inhibiting drugs such as barbiturates within 1 month before the first administration, or who have taken medications that may interfere with this clinical trial within 10 days before the first administration (however, participation may be allowed after considering pharmacokinetic and pharmacodynamic characteristics such as interactions with the product and drug half-life).
  • Subjects who have consumed grapefruit-containing foods within 7 days before the first administration or who are unable to refrain from consuming such foods during the clinical trial.
  • Subjects who have participated in another clinical trial or bioequivalence study and received an investigational product within 6 months before the first administration.
  • Subjects who have donated whole blood within 8 weeks before the first administration, donated blood components within 2 weeks, or received a blood transfusion within 4 weeks.
  • Subjects considered unsuitable for participation based on screening assessments performed within 30 days before the first administration of the investigational product.

    • or ALT > 1.5 × the .
    • Total > 1.5 × the upper limit of the normal range.
    • (estimated Glomerular Filtration Rate), calculated using the MDRD (Modification of Diet in Renal Disease) equation, \< 60 mL/min/1.73m².
    • Positive results for serologic tests (, , [HIV], or syphilis).
    • After at least 5 minutes of rest, seated vital signs showing systolic blood pressure > 139 mmHg or \< 100 mmHg, or diastolic blood pressure > 90 mmHg or \< 60 mmHg.
  • Subjects who meet any of the following conditions within 1 month before the first administration.

    • Average alcohol consumption exceeding 21 drinks/week for males.
    • Average alcohol consumption exceeding 14 drinks/week for females.

      (1 drink = 50 mL of soju, 30 mL of spirits, or 250 mL of beer.)

    • Smoking more than 10 cigarettes per day on average.
  • Subjects who meet any of the following conditions.

    • Subjects with to this drug or any of its components.
    • Subjects with hereditary problems of fructose or galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  • Subjects whom the Investigator (or delegated Sub-investigator) considers unsuitable for participation in this clinical trial for reasons other than the above inclusion/exclusion criteria (e.g., excessive tattoos).
  • Subjects with a history of drug abuse within 1 year before screening or those with a positive urine drug screening test.
  • Female subjects who are pregnant, suspected to be pregnant, or breastfeeding.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: Investigational Product 1 · Drug: Investigational Product 1 + Investigational Product 2

  • Experimental
    Arm B

    Drug: Investigational Product 2 · Drug: Investigational Product 1 + Investigational Product 2

Interventions

  • DrugInvestigational Product 1

    UIC202601 1Tab/day for 7 days

  • DrugInvestigational Product 2

    UIC202602 1Tab/day for 7 days

  • DrugInvestigational Product 1 + Investigational Product 2

    UIC202601+UIC202602 2Tab/day for 7 days

06

What researchers measure

Primary outcomes

  1. AUCτ,ss

    Evaluation PK

    Time frame: 0 to 24hr

  2. Cmax,ss

    Evaluation PK

    Time frame: 0 to 24hr

07

Study locations

1 of 1 sites recruiting
  • Metro Hospital
    Anyang, Manan-gu 14096, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Sep 2026, 2 months later.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 2 months is close to that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2026
First posted
Jul 6, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07682948
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jul 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion